Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | APLNR | P35414 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18673195 | 0.86 | HPGD (0.54) | APLNRGAAHTTSMN1; SMN2LMNA | |
| SCHEMBL27099061 | 0.86 | HTT (0.50) | KDM4EAPLNRGAAHTTTDP1 | |
| SCHEMBL1431992 | 0.86 | ALDH1A1 (0.50) | KDM4EAPLNRGAAHTTSMN1; SMN2 | |
| SCHEMBL15829741 | 0.85 | GAA (0.50) | KDM4EAPLNRGAATDP1SMN1; SMN2 | |
| SCHEMBL2068949 | 0.85 | GAA (0.49) | KDM4EAPLNRGAAHTTTDP1 | |
| SCHEMBL4317497 | 0.85 | HTT (0.49) | KDM4EAPLNRGAAHTTTDP1 | |
| SCHEMBL26196694 | 0.85 | ALDH1A1 (0.63) | APLNRGAAHTTSMN1; SMN2LMNA | |
| SCHEMBL26196749 | 0.85 | APLNR (0.51) | KDM4EAPLNRGAAHTTLMNA | |
| SCHEMBL13580096 | 0.85 | HTT (0.49) | KDM4EAPLNRGAAHTTTDP1 | |
| SCHEMBL16638802 | 0.85 | KDM4E (0.48) | KDM4EGAAHTTTDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912687-B2 | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof | Board of Trustees of the Southern Illinois University (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912687-B2 | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof | Board of Trustees of the Southern Illinois University (US) | 2024-02-27 | — | — | US | disclosed |
| EP-3634406-B1 | 3,4,5-TRISUBSTITUTED-1,2,4-TRIAZOLES AND 3,4,5-TRISUBSTITUTED-3-THIO-1,2,4-TRIAZOLES AND USES THEREOF | BOARD OF TRUSTEES OF THE SOUTHERN ILLINOIS UNIV ON BEHALF OF SOUTHERN ILLINOIS UNIV EDWARDSVILLE (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-3634406-B1 | 3,4,5-TRISUBSTITUTED-1,2,4-TRIAZOLES AND 3,4,5-TRISUBSTITUTED-3-THIO-1,2,4-TRIAZOLES AND USES THEREOF | BOARD OF TRUSTEES OF THE SOUTHERN ILLINOIS UNIV ON BEHALF OF SOUTHERN ILLINOIS UNIV EDWARDSVILLE (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20230043400-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20220002274-A1 | 3,4,5-Trisubstituted-1,2,4-Triazoles and 3,4,5-Trisubstituted-3-Thio-1,2,4-Triazoles and Uses Thereof | Board of Trustees of the Southern Illinois University (US) | 2022-01-06 | — | — | US | disclosed |
| US-11136312-B2 | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof | Board of Trustees of the Southern Illinois University (US) | 2021-10-05 | — | — | US | disclosed |
| US-11136312-B2 | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof | Board of Trustees of the Southern Illinois University (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200317691-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200165230-A1 | 3,4,5-Trisubstituted-1,2,4-Triazoles and 3,4,5-Trisubstituted-3-Thio-1,2,4-Triazoles and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-05-28 | — | — | US | disclosed |
| US-20150329539-A1 | 4-PYRIDINONETRIAZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150183782-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF HIV | MORGAN STANLEY SENIOR FUNDING, INC. | 2015-07-02 | — | — | US | disclosed |
| WO-2015095258-A1 | SPIROCYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015089847-A1 | SPIROCYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-8987272-B2 | Compounds and method for treatment of HIV | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2015-03-24 | — | — | US | disclosed |
| WO-2014099586-A1 | 4-PYRIDINONETRIAZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20130217693-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF HIV | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2013-08-22 | — | — | US | disclosed |
| EP-2540720-A1 | 1,3,4,8-TETRAHYDRO-2H-PYRIDO[1,2-A]PYRAZINE DERIVATIVE AND USE OF SAME AS HIV INTEGRASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-20120108564-A1 | 1,3,4,8-Tetrahydro-2H-Pyrido[1,2-a]Pyradine Derivatives and Use Thereof as HIV Integrase Inhibitor | JAPAN TOBACCO INC. (JP) | 2012-05-03 | — | — | US | disclosed |
| WO-2011120153-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF HIV | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317691-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | KDM4E 1466/4885APLNR 3948/4885GAA 2016/4885 |
| US-20200165230-A1 | 3,4,5-Trisubstituted-1,2,4-Triazoles and 3,4,5-Trisubstituted-3-Thio-1,2,4-Triazoles and Uses Thereof | SSTR4, SSTR3, SSTR5 | KDM4E 2603/4885APLNR 331/4885GAA 3125/4885 |
| US-20120108564-A1 | 1,3,4,8-Tetrahydro-2H-Pyrido[1,2-a]Pyradine Derivatives and Use Thereof as HIV Integrase Inhibitor | IMPDH1, IMPA1, DPYD | KDM4E 735/4885APLNR 4852/4885GAA 2362/4885 |
| US-20230043400-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | KDM4E 1466/4885APLNR 3948/4885GAA 2016/4885 |
| US-20130217693-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF HIV | NNT, CCR5, XDH | KDM4E 2192/4885APLNR 4659/4885GAA 1770/4885 |
| US-11136312-B2 | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof | SSTR4, SSTR3, SSTR5 | KDM4E 2603/4885APLNR 331/4885GAA 3125/4885 |
| US-20220002274-A1 | 3,4,5-Trisubstituted-1,2,4-Triazoles and 3,4,5-Trisubstituted-3-Thio-1,2,4-Triazoles and Uses Thereof | SSTR4, SSTR3, SSTR5 | KDM4E 2603/4885APLNR 331/4885GAA 3125/4885 |
| US-20150183782-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF HIV | NNT, CCR5, XDH | KDM4E 2192/4885APLNR 4659/4885GAA 1770/4885 |
| US-11912687-B2 | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof | SSTR4, SSTR5, SSTR3 | KDM4E 2801/4885APLNR 407/4885GAA 2970/4885 |
| US-20150329539-A1 | 4-PYRIDINONETRIAZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS | TYMP, TYMS, PNPO | KDM4E 220/4885APLNR 4826/4885GAA 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.